Dendritic/tumor fusion cells as cancer vaccines

Seminars in Oncology

Volumn 39, Issue 3, 2012, Pages 287-295

  Avigan, David ^a   Rosenblatt, Jacalyn ^a   Kufe, Donald ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHEMOKINE RECEPTOR CCR7; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; IMMUNOLOGICAL ADJUVANT; INDOLEAMINE; INTERLEUKIN 10; INTERLEUKIN 12; MUCIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; VASCULOTROPIN; VIRUS VECTOR;

ADD ON THERAPY; ANTIGEN PRESENTATION; ARTHRALGIA; ARTICLE; AUTOIMMUNITY; BLOOD TOXICITY; BREAST CARCINOMA; BREAST METASTASIS; CANCER CELL; CANCER IMMUNIZATION; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL MATURATION; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; COLON CANCER; DENDRITIC CELL; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG FEVER; DRUG POTENCY; ESOPHAGUS CANCER; GLIOMA; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE EXTRAVASATION; INJECTION SITE INDURATION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MULTIPLE MYELOMA; MYALGIA; MYELOID LEUKEMIA; MYELOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIDE EFFECT; SWELLING; T CELL DEPLETION; TH1 CELL; TH17 CELL; TUMOR ESCAPE; VACCINE PRODUCTION;

ANIMALS; CANCER VACCINES; CELL FUSION; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84861171729     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.02.003     Document Type: Article

References (99)

1. H.J. Kolb, A. Schattenberg, J.M. Goldman Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients Blood 86 1995 2041 2050
2. P.L. Weiden, K.M. Sullivan, N. Flournoy, R. Storb, E.D. Thomas Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation N Engl J Med 304 1981 1529 1533 (Pubitemid 11065939)
3. G. Gahrton, S. Tura, P. Ljungman Allogeneic bone marrow transplantation in multiple myeloma European Group for Bone Marrow Transplantation N Engl J Med 325 1991 1267 1273
4. G. Tricot, D.H. Vesole, S. Jagannath, J. Hilton, N. Munshi, B. Barlogie Graft-versus-myeloma effect: proof of principle Blood 87 1996 1196 1198 (Pubitemid 26043549)
5. B.B. Bjorkstrand, P. Ljungman, H. Svensson Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation Blood 88 1996 4711 4718 (Pubitemid 26419156)
6. Q. Yi, A. Osterborg, S. Bergenbrant, H. Mellstedt, G. Holm, A.K. Lefvert Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies Blood 86 1995 3043 3049
7. G.F. Lauritzsen, S. Weiss, Z. Dembic, B. Bogen Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors Proc Natl Acad Sci U S A 91 1994 5700 5704 (Pubitemid 24174396)
8. K. Silina, P. Zayakin, Z. Kalnina Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients J Immunother 34 2011 28 44
9. R.A. Madan, J.L. Gulley, P.M. Arlen PSA-based vaccines for the treatment of prostate cancer Expert Rev Vaccines 5 2006 199 209 (Pubitemid 44179951)
10. T. Takahashi, Y. Makiguchi, Y. Hinoda Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient J Immunol 153 1994 2102 2109 (Pubitemid 24256681)
11. P. Brossart, A. Schneider, P. Dill The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes Cancer Res 61 2001 6846 6850 (Pubitemid 32896509)
12. T. Boon, P. van der Bruggen Human tumor antigens recognized by T lymphocytes J Exp Med 183 1996 725 729 (Pubitemid 26113944)
13. Y. Kawakami, S. Eliyahu, C.H. Delgado Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection Proc Natl Acad Sci U S A 91 1994 6458 6462
14. D.E. Speiser, R. Miranda, A. Zakarian Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy J Exp Med 186 1997 645 653 (Pubitemid 27381529)
15. + T-cell memory in tumor immunology and immunotherapy Immunol Rev 211 2006 214 224 (Pubitemid 43882974)
16. H. Jonuleit, E. Schmitt, M. Stassen, A. Tuettenberg, J. Knop, A.H. Enk Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood J Exp Med 193 2001 1285 1294 (Pubitemid 32524778)
17. U.K. Liyanage, T.T. Moore, H.G. Joo Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma J Immunol 169 2002 2756 2761 (Pubitemid 34921025)
18. L.A. Ormandy, T. Hillemann, H. Wedemeyer, M.P. Manns, T.F. Greten, F. Korangy Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma Cancer Res 65 2005 2457 2464 (Pubitemid 40490158)
19. T.J. Curiel, G. Coukos, L. Zou Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 2004 942 949 (Pubitemid 39273735)
20. H. Dong, S.E. Strome, D.R. Salomao Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
21. J. Rosenblatt, B. Glotzbecker, H. Mills PD-1 Blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine J Immunother 34 2011 409 418
22. P.D. Gregor, J.D. Wolchok, C.R. Ferrone CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems Vaccine 22 2004 1700 1708 (Pubitemid 38447218)
23. J. Weber Immune checkpoint proteins: a new therapeutic paradigm for cancer - preclinical background: CTLA-4 and PD-1 blockade Semin Oncol 37 2010 430 439
24. D. Gabrilovich Mechanisms and functional significance of tumour-induced dendritic-cell defects Nat Rev Immunol 4 2004 941 952 (Pubitemid 39620069)
25. F. Ye, H.Z. Chen, X. Xie, D.F. Ye, W.G. Lu Ovarian carcinoma cells effectively inhibit differentiation and maturation of dendritic cells derived from hematopoietic progenitor cells in vitro Cancer Invest 23 2005 379 385 (Pubitemid 41324354)
26. D. Avigan Dendritic cells: development, function and potential use for cancer immunotherapy Blood Rev 13 1999 51 64 (Pubitemid 29178531)
27. R.M. Steinman The dendritic cell system and its role in immunogenicity Annu Rev Immunol 9 1991 271 296
28. J. Banchereau, R.M. Steinman Dendritic cells and the control of immunity Nature 392 1998 245 252 (Pubitemid 28155090)
29. M. O'Keeffe, H. Hochrein, D. Vremec Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte-macrophage colony-stimulating factor on dendritic cell subsets in mice Blood 99 2002 2122 2130 (Pubitemid 34525497)
30. B.I. Rini, A. Paintal, N.J. Vogelzang, T.F. Gajewski, W.M. Stadler Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity J Immunother 25 2002 269 277 (Pubitemid 34533317)
31. D.W. O'Neill, S. Adams, N. Bhardwaj Manipulating dendritic cell biology for the active immunotherapy of cancer Blood 104 2004 2235 2246 (Pubitemid 39331818)
32. P. Szabolcs, M.A. Moore, J.W. Young Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha J Immunol 154 1995 5851 5861
33. B. Ferraro, N.J. Cisper, K.T. Talbott Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses Hum Vaccin 7 2011 120 127
34. D. Li, S. Hua, Y. Fan DNA vaccine expressing repeated carcinoembryonic antigen (CEA)(625-667) induces strong immunity in mice Immunol Lett 135 2011 124 128
35. E. Signori, S. Iurescia, E. Massi et al. DNA vaccination strategies for anti-tumour effective gene therapy protocols Cancer Immunol Immunother 59 2010 1583 1591
36. D. Fioretti, S. Iurescia, V.M. Fazio, M. Rinaldi DNA vaccines: developing new strategies against cancer J Biomed Biotechnol 2010 174378
37. J.L. Gulley, P.M. Arlen, K.Y. Tsang Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma Clin Cancer Res 14 2008 3060 3069
38. H.L. Kaufman, S. Kim-Schulze, K. Manson Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer J Transl Med 5 2007 60
39. E. Lou, J. Marshall, M. Aklilu, D. Cole, D. Chang, M. Morse A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma Clin Colorectal Cancer 5 2006 368 371 (Pubitemid 43280069)
40. M.T. Litzinger, K.A. Foon, K.Y. Tsang, J. Schlom, C. Palena Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells Leuk Res 34 2010 1351 1357
41. M.T. Litzinger, K.A. Foon, H. Sabzevari, K.Y. Tsang, J. Schlom, C. Palena Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients Cancer Immunol Immunother 58 2009 955 965
42. R. Spisek, P. Chevallier, N. Morineau Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin Cancer Res 62 2002 2861 2868 (Pubitemid 34525772)
43. C.M. Celluzzi, J.I. Mayordomo, W.J. Storkus, M.T. Lotze, L.D. Falo Jr Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity J Exp Med 183 1996 283 287 (Pubitemid 26028768)
44. J.I. Mayordomo, T. Zorina, W.J. Storkus Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity Nat Med 1 1995 1297 1302
45. P. Paglia, C. Chiodoni, M. Rodolfo, M.P. Colombo Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo J Exp Med 183 1996 317 322 (Pubitemid 26028774)
46. K. Pan, J.J. Zhao, H. Wang Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma-derived RNA or cell lysate Int J Biol Sci 6 2010 639 648
47. R.J. Barth Jr, D.A. Fisher, P.K. Wallace A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival Clin Cancer Res 16 2010 5548 5556
48. Q. He, J. Li, W. Yin Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer Cancer Immunol Immunother 60 2011 715 730
49. E. Lutz, C.J. Yeo, K.D. Lillemoe et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma A phase II trial of safety, efficacy, and immune activation Ann Surg 253 2011 328 335
50. J. Olivares, P. Kumar, Y. Yu et al. Phase I trial of TGF-β2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine Clin Cancer Res 17 2011 183 192
51. G. Driessens, L. Nuttin, A. Gras et al. Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery Cancer Immunol Immunother 60 2011 273 281
52. J. Zilberberg, T.M. Friedman, G. Dranoff, R. Korngold Treatment with GM-CSF secreting myeloid leukemia cell vaccine prior to autologous-BMT improves the survival of leukemia-challenged mice Biol Blood Marrow Transplant 17 2011 330 340
53. V.T. Ho, M. Vanneman, H. Kim Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation Proc Natl Acad Sci U S A 106 2009 15825 15830
54. J. Rosenblatt, D. Kufe, D. Avigan Dendritic cell fusion vaccines for cancer immunotherapy Expert Opin Biol Ther 5 2005 703 715 (Pubitemid 40780553)
55. W.T. Lee Dendritic cell-tumor cell fusion vaccines Adv Exp Med Biol 713 2011 177 186
56. D. Cathelin, A. Nicolas, A. Bouchot, J. Fraszczak, J.R. Labb, B. Bonnotte Dendritic cell/tumor cell hybrids and immunotherapy: what's next? Cytotherapy 13 2011 774 785
57. S. Koido, E. Hara, S. Homma, T. Ohkusa, J. Gong, H. Tajiri Cancer immunotherapy by fusions of dendritic cells and tumor cells Immunotherapy 1 2009 49 62
58. J. Gong, S. Koido, S.K. Calderwood Cell fusion: from hybridoma to dendritic cell-based vaccine Expert Rev Vaccines 7 2008 1055 1068
59. J. Gong, D. Chen, M. Kashiwaba, D. Kufe Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells Nat Med 3 1997 558 561 (Pubitemid 27198656)
60. J. Gong, D. Chen, M. Kashiwaba Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells Proc Natl Acad Sci U S A 95 1998 6279 6283 (Pubitemid 28249003)
61. Y. Tanaka, S. Koido, M. Ohana, C. Liu, J. Gong Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells J Immunol 174 2005 1274 1280
62. J. Gong, D. Avigan, D. Chen Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells Proc Natl Acad Sci U S A 97 2000 2715 2718 (Pubitemid 30159237)
63. J. Gong, N. Nikrui, D. Chen Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity J Immunol 165 2000 1705 1711 (Pubitemid 30604610)
64. B. Vasir, V. Borges, Z. Wu Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation Br J Haematol 129 2005 687 700 (Pubitemid 40825831)
65. Z. Yu, B. Ma, Y. Zhou Allogeneic tumor vaccine produced by electrofusion between osteosarcoma cell line and dendritic cells in the induction of antitumor immunity Cancer Invest 25 2007 535 541 (Pubitemid 350135732)
66. S. Homma, G. Toda, J. Gong, D. Kufe, T. Ohno Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice J Gastroenterol 36 2001 764 771 (Pubitemid 33133502)
67. J.Y. Yang, D.Y. Cao, L.Y. Ma, W.C. Liu Dendritic cells fused with allogeneic hepatocellular carcinoma cell line compared with fused autologous tumor cells as hepatocellular carcinoma vaccines Hepatol Res 40 2010 505 513
68. D.Y. Cao, J.Y. Yang, S.Q. Yue Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma Cell Immunol 259 2009 13 20
69. G.A. Banat, N. Usluoglu, M. Hoeck, K. Ihlow, S. Hoppmann, H. Pralle Dendritic cells fused with core binding factor-beta positive acute myeloid leukaemia blast cells induce activation of cytotoxic lymphocytes Br J Haematol 126 2004 593 601 (Pubitemid 39093103)
70. J. Gong, S. Koido, Y. Kato Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts Leuk Res 28 2004 1303 1312 (Pubitemid 39314410)
71. T.B. Kim, H.K. Park, J.H. Chang et al. The establishment of dendritic cell-tumor fusion vaccines for hormone refractory prostate cancer cell Korean J Urol 51 2010 139 144
72. Z. Hu, S. Liu, X. Mai, C. Liu Anti-tumor effects of fusion vaccine prepared by renal cell carcinoma 786-O cell line and peripheral blood dendritic cells of healthy volunteers in vitro and in human immune reconstituted SCID mice Cell Immunol 262 2010 112 119
73. F. Xu, Y.J. Ye, W. Liu, M. Kong, Y. He, S. Wang Dendritic cell/tumor hybrids enhances therapeutic efficacy against colorectal cancer liver metastasis in SCID mice Scand J Gastroenterol 45 2010 707 713
74. G.H. Guo, S.Z. Chen, J. Yu In vivo anti-tumor effect of hybrid vaccine of dendritic cells and esophageal carcinoma cells on esophageal carcinoma cell line 109 in mice with severe combined immune deficiency World J Gastroenterol 14 2008 1167 1174 (Pubitemid 351356323)
75. K. Serhal, C. Baillou, N. Ghinea Characteristics of hybrid cells obtained by dendritic cell/tumour cell fusion in a T-47D breast cancer cell line model indicate their potential as anti-tumour vaccines Int J Oncol 31 2007 1357 1365
76. J. Galea-Lauri, J.W. Wells, D. Darling, P. Harrison, F. Farzaneh Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination Cancer Immunol Immunother 53 2004 963 977 (Pubitemid 39371741)
77. J. Galea-Lauri, D. Darling, G. Mufti, P. Harrison, F. Farzaneh Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination Cancer Immunol Immunother 51 2002 299 310 (Pubitemid 34743982)
78. K. Shimizu, H. Kuriyama, J. Kjaergaard, W. Lee, H. Tanaka, S. Shu Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy J Immunother 27 2004 265 272 (Pubitemid 38833322)
79. R.V. Goddard, A.G. Prentice, J.A. Copplestone, E.R. Kaminski In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids Clin Exp Immunol 131 2003 82 89 (Pubitemid 36098826)
80. J. Rosenblatt, B. Vasir, L. Uhl et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma Blood 117 2011 393 402
81. D. Avigan, D.J. George, P.W. Kantoff Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma J Clin Oncol ASCO Annual Meeting Proceedings 22 2004 169 [abstract]
82. D. Avigan, B. Vasir, J. Gong Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses Clin Cancer Res 10 2004 4699 4708 (Pubitemid 38955520)
83. D.E. Avigan, B. Vasir, D.J. George Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma J Immunother (1997) 30 2007 749 761 (Pubitemid 47480758)
84. G. Bianchi, G. Borgonovo, V. Pistoia, L. Raffaghello Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells Histol Histopathol 26 2011 941 951
85. S. Solito, V. Bronte, S. Mandruzzato Antigen specificity of immune suppression by myeloid-derived suppressor cells J Leukoc Biol 90 2011 31 36
86. T. Tadmor, D. Attias, A. Polliack Myeloid-derived suppressor cells - their role in haemato-oncological malignancies and other cancers and possible implications for therapy Br J Haematol 153 2011 557 567
87. B.F. Zamarron, W. Chen Dual roles of immune cells and their factors in cancer development and progression Int J Biol Sci 7 2011 651 658
88. B. Vasir, Z. Wu, K. Crawford Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells J Immunol 181 2008 808 821
89. J. Gong, S. Koido, D. Chen Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12 Blood 99 2002 2512 2517 (Pubitemid 34525439)
90. J. Rosenblatt, Z. Wu, B. Vasir et al. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28 J Immunother 33 2010 155 166
91. E.I. Cho, C. Tan, G.K. Koski, P.A. Cohen, S. Shu, W.T. Lee Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines Head Neck 32 2010 700 707
92. D. Xia, F. Li, J. Xiang Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity Cancer Biother Radiopharm 19 2004 322 330 (Pubitemid 38924496)
93. E. Alvarez, E. Moga, J. Barquinero, J. Sierra, J. Briones Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response Gene Ther 17 2010 469 477
94. M. Yamamoto, T. Kamigaki, K. Yamashita Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer Oncol Rep 22 2009 337 343
95. I. Borrello, E.M. Sotomayor, F.M. Rattis, S.K. Cooke, L. Gu, H.I. Levitsky Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines Blood 95 2000 3011 3019 (Pubitemid 30321148)
96. K.M. Williams, F.T. Hakim, R.E. Gress T cell immune reconstitution following lymphodepletion Semin Immunol 19 2007 318 330 (Pubitemid 350181530)
97. J. Rosenblatt, I. Avivi, B. Vasir Dendritic cell tumor fusion vaccination in conjunction with autologous transplantation for multiple myeloma ASH Annual Meeting Abstracts 114 2009 783 [abstract]
98. M.E. Keir, M.J. Butte, G.J. Freeman, A.H. Sharpe PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 2008 677 704 (Pubitemid 351600389)
99. M.E. Keir, L.M. Francisco, A.H. Sharpe PD-1 and its ligands in T-cell immunity Curr Opin Immunol 19 2007 309 314 (Pubitemid 46687017)